Melanoma-associated antigen 2 (MAGE-A2)-derived HLA-A*0201-restricted epitope (MAGE-A2/HLA-A*0201)

The Melanoma-associated antigen 2 (MAGE-A2)-derived HLA-A*0201-restricted epitope is a peptide-MHC complex that serves as a critical target for cancer immunotherapy (UniProt: P43356). MAGE-A2 is a member of the cancer-testis antigen family, characterized by high expression in various tumors—including melanoma, lung, and head and neck cancers—while remaining silent in normal adult tissues except for the testis and placenta (PubMed: 10449134). The specific epitope is a short peptide sequence from MAGE-A2 that is processed and presented by the HLA-A*0201 molecule, the most prevalent MHC Class I allele in many populations. This presentation allows the immune system, specifically CD8+ T cells, to identify and eliminate malignant cells through T-cell receptor (TCR) recognition (PubMed: 25103305). Therapeutic strategies targeting this epitope include TCR-engineered T cells (TCR-T) and cancer vaccines designed to elicit a robust anti-tumor immune response. Because of the high sequence homology among MAGE family members, a primary challenge in targeting this epitope is ensuring specificity to prevent off-target toxicity against healthy tissues. Monitoring MAGE-A2 expression and HLA-A*0201 status is essential for patient selection in clinical settings (ClinicalTrials.gov).

Other names

MAGE-A2 peptideMAGE-A2 epitopeHLA-A*02:01-restricted MAGE-A2 peptideMAGE-A2/HLA-A*02:01 complexMelanoma antigen family A 2 epitope

T-cell receptor (TCR) mediated recognition of the peptide-MHC complex leading to cytotoxic T-lymphocyte (CTL) activation and targeted tumor cell lysis.